Acute Graft-versus-Host Disease: Novel Biological Insights

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 1, 2016, Pages 11-16

  Teshima, Takanori ^a   Reddy, Pavan ^b   Zeiser, Robert ^c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Butyrate; Graft versus host disease; Histone deacetylase; Intestinal stem cells; Janus kinase; Paneth cells; Ruxolitinib

Indexed keywords

CYTOKINE; JANUS KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ENZYME INHIBITION; HISTONE ACETYLATION; HOMEOSTASIS; HUMAN; INTESTINAL STEM CELL; INTESTINE FLORA; METABOLOME; PANETH CELL; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; ACUTE DISEASE; ALLOGRAFT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INTESTINAL DISEASES; MORTALITY; PATHOLOGY; STOMACH DISEASES; T LYMPHOCYTE;

ACUTE DISEASE; ALLOGRAFTS; CYTOKINES; GASTROINTESTINAL MICROBIOME; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL DISEASES; PANETH CELLS; SIGNAL TRANSDUCTION; STOMACH DISEASES; T-LYMPHOCYTES;

EID: 84952639589     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.001     Document Type: Review

References (91)

1. Hill G.R., Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000, 95:2754-2759.
2. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
3. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
4. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
5. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003, 4:154-160.
6. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012, 367:135-145.
7. Kennedy G.A., Varelias A., Vuckovic S., et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014, 15:1451-1459.
8. Epstein R.J., McDonald G.B., Sale G.E., et al. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology 1980, 78:764-771.
9. Sale G.E., Shulman H.M., McDonald G.B., Thomas E.D. Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am J Surg Pathol 1979, 3:291-299.
10. Wall A.J., Rosenberg J.L., Reilly R.W. Small intestinal injury in the immunologically runted mouse. Morphologic and autoradiographic studies. J Lab Clin Med 1971, 78:833-834.
11. Hanash A.M., Dudakov J.A., Hua G., et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37:339-350.
12. Takashima S., Kadowaki M., Aoyama K., et al. The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. J Exp Med 2011, 208:285-294.
13. Eriguchi Y., Takashima S., Oka H., et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood 2012, 120:223-231.
14. van Es J.H., Sato T., van de Wetering M., et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat Cell Biol 2012, 14:1099-1104.
15. Ayabe T., Satchell D.P., Wilson C.L., et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1:113-118.
16. Eriguchi Y., Nakamura K., Hashimoto D., et al. Decreased secretion of Paneth cell alpha-defensin in graft-versus-host disease. Transplant Infect Dis 2015, 17:702-706.
17. Jenq R.R., Ubeda C., Taur Y., et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012, 209:903-911.
18. Heimesaat M.M., Nogai A., Bereswill S., et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 2010, 59:1079-1087.
19. Tawara I., Liu C., Tamaki H., et al. Influence of donor microbiota on the severity of experimental graft-versus-host-disease. Biol Blood Marrow Transplant 2013, 19:164-168.
20. Pelaseyed T., Bergstrom J.H., Gustafsson J.K., et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 2014, 260:8-20.
21. Penack O., Holler E., van den Brink M.R. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010, 115:1865-1872.
22. Cantoni N., Hirsch H.H., Khanna N., et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:1309-1314.
23. Taur Y., Xavier J.B., Lipuma L., et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012, 55:905-914.
24. Levine J.E., Huber E., Hammer S.T., et al. Low Paneth cell numbers at onset of gastrointestinal GVHD identify patients at high risk for non-relapse mortality. Blood 2013, 122:1505-1509.
25. Taur Y., Jenq R.R., Perales M.A., et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014, 124:1174-1182.
26. Holler E., Butzhammer P., Schmid K., et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:640-645.
27. Schwab L., Goroncy L., Palaniyandi S., et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med 2014, 20:648-654.
28. Reinhardt K., Foell D., Vogl T., et al. Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease. J Immunol 2014, 193:3355-3365.
29. van Bekkum D.W., Roodenburg J., Heidt P.J., van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Nat Cancer Inst 1974, 52:401-404.
30. Jones J.M., Wilson R., Bealmear P.M. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971, 45:577-588.
31. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
32. van der Velden W.J., Plantinga T.S., Feuth T., et al. The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status. Clin Immunol 2010, 136:302-306.
33. Uryu H., Hashimoto D., Kato K., et al. alpha-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. Blood 2015, 125:3014-3023.
34. Varelias A., Gartlan K.H., Kreijveld E., et al. Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. Blood 2015, 125:2435-2444.
35. Muranski P., Restifo N.P. Essentials of Th17 cell commitment and plasticity. Blood 2013, 121:2402-2414.
36. Gartlan K.H., Markey K.A., Varelias A., et al. Tc17 cells are a pro-inflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without anti-leukemic effects. Blood 2015, 126:1609-1620.
37. Dudakov J.A., Hanash A.M., van den Brink M.R. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 2015, 33:747-785.
38. Kim K.A., Kakitani M., Zhao J., et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 2005, 309:1256-1259.
39. Sato T., Vries R.G., Snippert H.J., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
40. Jenq R., Taur Y., Devlin S., et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 2015, 21:1373-1383.
41. Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999, 104:317-325.
42. Sostak P., Padovan C.S., Yousry T.A., et al. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003, 60:842-848.
43. Shanis D., Merideth M., Pulanic T.K., et al. Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. Semin Hematol 2012, 49:83-93.
44. Hartrampf S., Dudakov J.A., Johnson L.K., et al. The central nervous system is a target of acute graft versus host disease in mice. Blood 2013, 121:1906-1910.
45. Kaliyaperumal S., Watkins B., Sharma P., et al. CD8-predominant T cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. Blood 2014, 123:1967-1969.
46. Shimoji S., Hashimoto D., Kato K., et al. Graft-versus-host disease targets granulosa cell of ovarian follicle and causes infertility after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015, 21:S26-S27.
47. Choi S.W., Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol 2014, 11:536-547.
48. Choi S., Reddy P. HDAC inhibition and graft versus host disease. Mol Med 2011, 17:404-416.
49. Reddy P., Sun Y., Toubai T., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008, 118:2562-2573.
50. Choi S.W., Gatza E., Hou G., et al. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood 2015, 125:815-819.
51. Choi S.W., Braun T., Chang L., et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014, 15:87-95.
52. Glauben R., Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med 2011, 17:426-433.
53. Kabat A.M., Srinivasan N., Maloy K.J. Modulation of immune development and function by intestinal microbiota. Trends Immunol 2014, 35:507-517.
54. Young V.B. The intestinal microbiota in health and disease. Curr Opin Gastroenterol 2012, 28:63-69.
55. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
56. Donohoe D.R., Garge N., Zhang X., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabol 2011, 13:517-526.
57. Atarashi K., Tanoue T., Oshima K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500:232-236.
58. Furusawa Y., Obata Y., Fukuda S., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-450.
59. De Vadder F., Kovatcheva-Datchary P., Goncalves D., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156:84-96.
60. Wong J.M., de Souza R., Kendall C.W., et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006, 40:235-243.
61. Mathewson M., Mathew A., Oravecz-Wilson K., et al. Unbiased metabolic profiling uncovers a crucial role for the microbial metabolite butyrate in modulating GI epithelial cell damage from GVHD. Blood 2014, 124:536.
62. Iyengar S., Zhan C., Lu J., et al. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014, 8:1104-1111.
63. Haarberg K.M., Li J., Heinrichs J., et al. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood 2013, 122:2500-2511.
64. Valenzuela J.O., Iclozan C., Hossain M.S., et al. PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest 2009, 119:3774-3786.
65. Leonhardt F., Zirlik K., Buchner M., et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia 2012, 26:1617-1629.
66. Le Huu D., Kimura H., Date M., et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. J Dermatol Sci 2014, 74:214-221.
67. Flynn R., Allen J.L., Luznik L., et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood 2015, 125:4085-4094.
68. Allen J.L., Tata P.V., Fore M.S., et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 2014, 123:2108-2115.
69. Carniti C., Gimondi S., Vendramin A., et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res 2015, 21:3740-3749.
70. Spoerl S., Mathew N.R., Bscheider M., et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014, 123:3832-3842.
71. Choi J., Cooper M.L., Alahmari B., et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One 2014, 9:e109799.
72. Hechinger A.K., Smith B.A., Flynn R., et al. Therapeutic activity of multiple common gamma chain cytokine inhibition in acute and chronic GvHD. Blood 2015, 125:570-580.
73. Cetkovic-Cvrlje M., Roers B.A., Waurzyniak B., et al. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001, 98:1607-1613.
74. Nellore A., Liu B., Patsoukis N., et al. The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors. Clin Immunol 2014, 152:48-57.
75. Shindo T., Kim T.K., Benjamin C.L., et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood 2013, 121:4617-4626.
76. Cetkovic-Cvrlje M., Uckun F.M. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004, 126:821-827.
77. Martelli M.P., Lin H., Zhang W., et al. Signaling via LAT (linker for T cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation. Blood 2000, 96:2181-2190.
78. Tang B., Zhou J., Park J.E., et al. T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol 2009, 133:145-153.
79. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-20063.
80. He Y.W., Adkins B., Furse R.K., et al. Expression and function of the gamma c subunit of the IL-2, IL-4, and IL-7 receptors. Distinct interaction of gamma c in the IL-4 receptor. J Immunol 1995, 154:1596-1606.
81. Heine A., Held S.A., Daecke S.N., et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013, 122:1192-1202.
82. Nicholson S.E., Oates A.C., Harpur A.G., et al. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. PNAS 1994, 91:2985-2988.
83. Schwab L., Goroncy L., Palaniyandi S., et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. Nat Med 2014, 20:648-654.
84. Giroux M., Delisle J.S., Gauthier S.D., et al. SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood 2011, 117:1734-1744.
85. Socié G., Mary J.Y., Lemann M., et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood 2004, 103:50-57.
86. Zeiser R., Burchert A., Lengerke C., et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia 2015, 29:2062-2068.
87. Martin P., Rizzo J.D., Wingard J.R., et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012, 18:1150-1163.
88. MacMillan M.L., Weisdorf D.F., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:40-46.
89. Rager A., Frey N., Goldstein S.C., et al. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow Transplant 2011, 46:430-435.
90. Schnitzler M., Hasskarl J., Egger M., et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009, 15:910-918.
91. Schub N., Gunther A., Schrauder A., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011, 46:143-147.